This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barnes, C. J. Articles by Kumar, R. Search for Related Content PubMed PubMed Citation Articles by Barnes, C. J. Articles by Kumar, R.

Heregulin Induces Expression, ATPase Activity, and Nuclear Localization of G3BP, a Ras Signaling Component, in Human Breast Tumors¹

Departments of Molecular and Cellular Oncology [C. J. B., F. L., M. M., Z. Y., R. K.] and Pathology [A. A. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

We have found using differential display of mRNA that the growth factor heregulin ß1 (HRG), a combinatorial ligand for human epidermal growth factor receptors (HERs), induced expression of G3BP, the Ras GTPase-activating protein SH3 domain-binding protein, in breast cancer cells. G3BP is a downstream effector protein of Ras signaling with ATP-dependent RNase and helicase activities, which may link Ras signaling with RNA turnover and cell cycle progression. In human breast cancer cells, HRG induced G3BP mRNA and protein expression. Up-regulation of G3BP was found in MCF7 breast cancer cells overexpressing HER2. G3BP was also overexpressed in human breast tumors in parallel with HER2 overexpression and in an estrogen-independent manner, suggesting a role for G3BP in cancer progression. In addition, HRG stimulation of breast cancer cells promoted phosphorylation of G3BP and increased the association of G3BP with GTPase-activating protein, both of which are essential for G3BP activity. G3BP ATPase activity was also significantly increased by HRG treatment. Furthermore, HRG treatment resulted in G3BP translocation to the nucleus and colocalization with acetylated histone H3, a hallmark of active transcription sites. G3BP induction, phosphorylation, ATPase activity, and relocalization after HRG treatment could all be blocked by pretreatment with the anti-receptor HER2 monoclonal antibody Herceptin (trastuzumab), which may suggest additional applications for this therapeutic antibody. These findings demonstrate for the first time the receptor-dependent regulation of G3BP, a downstream effector of Ras signaling, by HRG, a growth factor with diverse functions in breast cancer cells.

This article has been cited by other articles:

				D. M. Langenau, M. D. Keefe, N. Y. Storer, J. R. Guyon, J. L. Kutok, X. Le, W. Goessling, D. S. Neuberg, L. M. Kunkel, and L. I. Zon Effects of RAS on the genesis of embryonal rhabdomyosarcoma Genes & Dev., June 1, 2007; 21(11): 1382 - 1395. [Abstract] [Full Text] [PDF]

				Y.-H. Lin, J. Friederichs, M. A. Black, J. Mages, R. Rosenberg, P. J. Guilford, V. Phillips, M. Thompson-Fawcett, N. Kasabov, T. Toro, et al. Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer Clin. Cancer Res., January 15, 2007; 13(2): 498 - 507. [Abstract] [Full Text] [PDF]

				B. Wang, M. D. David, and J. W. Schrader Absence of Caprin-1 Results in Defects in Cellular Proliferation J. Immunol., October 1, 2005; 175(7): 4274 - 4282. [Abstract] [Full Text] [PDF]

				C. J. Barnes, F. Li, A. H. Talukder, and R. Kumar Growth Factor Regulation of a 26S Proteasomal Subunit in Breast Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2868 - 2874. [Abstract] [Full Text] [PDF]

				S. Rahmouni, T. Vang, A. Alonso, S. Williams, M. van Stipdonk, C. Soncini, M. Moutschen, S. P. Schoenberger, and T. Mustelin Removal of C-Terminal Src Kinase from the Immune Synapse by a New Binding Protein Mol. Cell. Biol., March 15, 2005; 25(6): 2227 - 2241. [Abstract] [Full Text] [PDF]

				Y. Zhang and A. W. Hamburger Heregulin Regulates the Ability of the ErbB3-binding Protein Ebp1 to Bind E2F Promoter Elements and Repress E2F-mediated Transcription J. Biol. Chem., June 18, 2004; 279(25): 26126 - 26133. [Abstract] [Full Text] [PDF]

				Z. Yang, C. J. Barnes, and R. Kumar Human Epidermal Growth Factor Receptor 2 Status Modulates Subcellular Localization of and Interaction with Estrogen Receptor {alpha} in Breast Cancer Cells Clin. Cancer Res., June 1, 2004; 10(11): 3621 - 3628. [Abstract] [Full Text] [PDF]

				Z. Yang, R. Bagheri-Yarmand, S. Balasenthil, G. Hortobagyi, A. A. Sahin, C. J. Barnes, and R. Kumar HER2 Regulation of Peroxisome Proliferator-activated Receptor {gamma} (PPAR{gamma}) Expression and Sensitivity of Breast Cancer Cells to PPAR{gamma} Ligand Therapy Clin. Cancer Res., August 1, 2003; 9(8): 3198 - 3203. [Abstract] [Full Text] [PDF]

				M. A. Kouvaraki, G. Z. Rassidakis, L. Tian, R. Kumar, C. Kittas, and F.-X. Claret Jun Activation Domain-binding Protein 1 Expression in Breast Cancer Inversely Correlates with the Cell Cycle Inhibitor p27Kip1 Cancer Res., June 1, 2003; 63(11): 2977 - 2981. [Abstract] [Full Text] [PDF]

				A. H. Talukder, S. K. Mishra, M. Mandal, S. Balasenthil, S. Mehta, A. A. Sahin, C. J. Barnes, and R. Kumar MTA1 Interacts with MAT1, a Cyclin-dependent Kinase-activating Kinase Complex Ring Finger Factor, and Regulates Estrogen Receptor Transactivation Functions J. Biol. Chem., March 21, 2003; 278(13): 11676 - 11685. [Abstract] [Full Text] [PDF]